Lieke L. Smits
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lieke L. Smits has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Wiesje Maria van der Flier
Neurodegeneration, Amsterdam Neuroscience, Amsterdam, Netherlands
5 shared publications Philip Scheltens
Alzheimer Center and Departments of Neurology, VU University Medical Center, Amsterdam, The Netherlands
4 shared publicationsIlona E.W. Reuling
Alzheimer Center and Departments of Medical Psychology, VU University Medical Center, Amsterdam, The Netherlands
3 shared publicationsYolande A.L. Pijnenburg
Alzheimer Center and Departments of Neurology, VU University Medical Center, Amsterdam, The Netherlands
3 shared publicationsAnnelies E. van der Vlies
Alzheimer Center and Departments of Neurology, VU University Medical Center, Amsterdam, The Netherlands
2 shared publicationsEsther L.G.E. Koedam
Alzheimer Center and Departments of Neurology, VU University Medical Center, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 1 July 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25 (7) , 1010-1017
Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains
- 1 July 2015
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 25 (7) , 1010-1017
Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains
- Open Access
- 31 December 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 1-8
The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical data and biomaterials from patients suffering from chronic diseases (so called “Pearls”) are collected according to harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis, differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer’s disease. The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as baseline descriptive variables, including their biomarker profile. The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients, respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%). The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and biomaterials of more than 1000 patients with cognitive impairments. The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset.
- 31 December 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 1-8
Open AccessThe Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical data and biomaterials from patients suffering from chronic diseases (so called “Pearls”) are collected according to harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis, differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer’s disease. The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as baseline descriptive variables, including their biomarker profile. The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients, respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%). The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and biomaterials of more than 1000 patients with cognitive impairments. The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset.
- 8 November 2013
- Published by Wiley in Alzheimer's & Dementia
- Vol. 10 (5S) , S299-305
Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease
Background: In Alzheimer's disease (AD), some patients present with cognitive impairment other than episodic memory disturbances. We evaluated whether occurrence of posterior atrophy (PA) and medial temporal lobe atrophy (MTA) could account for differences in cognitive domains affected.Methods: In 329 patients with AD, we assessed five cognitive domains: memory, language, visuospatial functioning, executive functioning, and attention. Magnetic resonance imaging (MRI) was rated visually for the presence of MTA and PA. Two‐way analyses of variance were performed with MTA and PA as independent variables, and cognitive domains as dependent variables. Gender, age, and education were covariates. As PA is often encountered in younger patients, analyses were repeated after stratification for age of onset (early onset, ≤ 65 years).Results: The mean age of the participants was 67 years, 175 (53%) were female, and the mean Mini‐Mental State Examination (score ± standard deviation) was 20 ± 5 points. Based on dichotomized magnetic resonance imaging ratings, 84 patients (26%) had MTA and PA, 98 (30%) had MTA, 57 (17%) had PA, and 90 (27%) had neither. MTA was associated with worse performance on memory, language, and attention (all, P < .05), and PA was associated with worse performance on visuospatial and executive functioning (both, P < .05). Stratification for age showed in patients with late‐onset AD (n = 173) associations between MTA and impairment on memory, language, visuospatial functioning, and attention (all, P < .05); in early‐onset AD (n = 156), patients with PA tended to perform worse on visuospatial functioning.Conclusions: Regional atrophy is related to impairment in specific cognitive domains in AD. The prevalence of PA in a large set of patients with AD and its association with cognitive functioning provides support for the usefulness of this visual rating scale in the diagnostic evaluation of AD.
- 8 November 2013
- Published by Wiley in Alzheimer's & Dementia
- Vol. 10 (5S) , S299-305
Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease
Background: In Alzheimer's disease (AD), some patients present with cognitive impairment other than episodic memory disturbances. We evaluated whether occurrence of posterior atrophy (PA) and medial temporal lobe atrophy (MTA) could account for differences in cognitive domains affected.Methods: In 329 patients with AD, we assessed five cognitive domains: memory, language, visuospatial functioning, executive functioning, and attention. Magnetic resonance imaging (MRI) was rated visually for the presence of MTA and PA. Two‐way analyses of variance were performed with MTA and PA as independent variables, and cognitive domains as dependent variables. Gender, age, and education were covariates. As PA is often encountered in younger patients, analyses were repeated after stratification for age of onset (early onset, ≤ 65 years).Results: The mean age of the participants was 67 years, 175 (53%) were female, and the mean Mini‐Mental State Examination (score ± standard deviation) was 20 ± 5 points. Based on dichotomized magnetic resonance imaging ratings, 84 patients (26%) had MTA and PA, 98 (30%) had MTA, 57 (17%) had PA, and 90 (27%) had neither. MTA was associated with worse performance on memory, language, and attention (all, P < .05), and PA was associated with worse performance on visuospatial and executive functioning (both, P < .05). Stratification for age showed in patients with late‐onset AD (n = 173) associations between MTA and impairment on memory, language, visuospatial functioning, and attention (all, P < .05); in early‐onset AD (n = 156), patients with PA tended to perform worse on visuospatial functioning.Conclusions: Regional atrophy is related to impairment in specific cognitive domains in AD. The prevalence of PA in a large set of patients with AD and its association with cognitive functioning provides support for the usefulness of this visual rating scale in the diagnostic evaluation of AD.
- 4 May 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 30 (1) , 101-108
Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile
Alzheimer's disease (AD) in younger patients is associated with a higher prevalence of atypical symptoms. We examined neuropsychological performance according to age-at-onset. We assessed cognition in 172 patients with AD (81 early and 91 late onset)
- 4 May 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 30 (1) , 101-108
Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile
Alzheimer's disease (AD) in younger patients is associated with a higher prevalence of atypical symptoms. We examined neuropsychological performance according to age-at-onset. We assessed cognition in 172 patients with AD (81 early and 91 late onset)
- 27 November 2010
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 31 (1) , 1-6
EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimer’s Disease
Objective: Our purpose was to investigate associations between different cognitive profiles and their underlying functional brain changes as measured by electroencephalogram (EEG) in Alzheimer’s disease (AD). Methods: EEG was obtained and neuropsychological performance assessed in 254 patients with AD. The EEGs were visually assessed for the presence of focal and/or diffuse abnormalities. Multivariate analysis of variance for repeated measures was performed with presence of focal and/or diffuse abnormalities as between-subjects factor and neuropsychological tests as within-subject factor. Age, sex and education were entered as covariates. Results: Twenty-eight percent of the patients had a normal EEG, 32% had focal abnormalities, 14% diffuse abnormalities and 26% had both focal and diffuse abnormalities. Patients with a normal EEG presented with a cognitive profile in which memory was mostly impaired. Patients with focal and diffuse EEG abnormalities presented with a nonmemory profile. Conclusion: These results illustrate that specific types of EEG abnormalities are associated with different cognitive profiles in AD, providing biological support in terms of brain functioning for variability in cognitive impairment.
- 27 November 2010
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 31 (1) , 1-6
EEG Abnormalities Are Associated with Different Cognitive Profiles in Alzheimer’s Disease
Objective: Our purpose was to investigate associations between different cognitive profiles and their underlying functional brain changes as measured by electroencephalogram (EEG) in Alzheimer’s disease (AD). Methods: EEG was obtained and neuropsychological performance assessed in 254 patients with AD. The EEGs were visually assessed for the presence of focal and/or diffuse abnormalities. Multivariate analysis of variance for repeated measures was performed with presence of focal and/or diffuse abnormalities as between-subjects factor and neuropsychological tests as within-subject factor. Age, sex and education were entered as covariates. Results: Twenty-eight percent of the patients had a normal EEG, 32% had focal abnormalities, 14% diffuse abnormalities and 26% had both focal and diffuse abnormalities. Patients with a normal EEG presented with a cognitive profile in which memory was mostly impaired. Patients with focal and diffuse EEG abnormalities presented with a nonmemory profile. Conclusion: These results illustrate that specific types of EEG abnormalities are associated with different cognitive profiles in AD, providing biological support in terms of brain functioning for variability in cognitive impairment.